Centro Médico Sheba
| Israel | Turquia | Áustria | |
| Terapia de protão | de $48,000 | de $70,000 | de $80,000 |
| Quimioterapia para cancro da mama | de $22,500 | de $1,200 | de $15,000 |
| Quimioterapia Intraperitoneal Hipertérmica (HIPEC) | de $61,200 | de $22,500 | de $40,000 |
| Prostatectomia robótica da Vinci | de $24,570 | de $17,000 | de $20,000 |
| CyberKnife | de $17,500 | de $4,750 | de $50,000 |
A Bookimed não adiciona taxas extras aos preços de tratamento de Adenocarcinoma. As tarifas vêm das listas oficiais de preços das clínicas. O pagamento é feito diretamente na clínica na chegada ao país.
A Bookimed está comprometida com sua segurança. Trabalha apenas com instituições que mantêm altos padrões internacionais no tratamento de Adenocarcinoma e têm as licenças necessárias para atender pacientes internacionais em todo o mundo.
A Bookimed oferece assistência gratuita de especialistas. Um coordenador médico pessoal apoia antes, durante e após o tratamento, solucionando problemas. Nunca está sozinho em sua jornada de tratamento de Adenocarcinoma.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.
He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.
Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.
Dr. Shira Felder is a senior radiation oncologist. She focuses on gynecologic and urologic cancers. She has advanced expertise in VMAT, IMRT, SBRT, and gynecologic brachytherapy. She delivers precise treatment with fewer side effects.
She heads the Gynecologic Oncology Service at Sheba Medical Center. She is a senior physician in the Radiation Oncology Division. She earned her MD at Hadassah. She completed residency at Sheba and a fellowship in the Radiation Medicine Program at the University of Toronto and Princess Margaret Cancer Centre. She is board-certified in Radiation Oncology. She is a member of ESTRO, the Israeli oncology societies, the CPSO, and the CMA.
Her research covers brachytherapy patient safety. It also includes stereotactic ablative radiotherapy for stage I lung cancer. She has studied treatment delays in cervical cancer. She has examined vitamin D deficiency in oncology patients.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.